Expression data from LNCaP cells treated with DHT and enzalutamide

GSE44905

Homo sapiens

18 Downloadable Samples

Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)

Submitter Supplied Information

Description

Enzalutamide (formerly MDV3100 and available commercially as Xtandi), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clinical study to increase survival in patients with metastatic CRPC. Enzalutamide inhibits multiple steps of AR signaling: (1) binding of androgens to AR, (2) AR nuclear translocation, and (3) association of AR with DNA.

PubMed ID

23765603

Publication Title

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Total Samples

Submitter’s Institution

Fundacion Ciencia y Vida

Authors

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S

Source Repository

Gene Expression Omnibus (GEO)

No rows found